New drug cocktail shows promise in shrinking breast tumors before surgery
NCT ID NCT04481113
First seen Jan 30, 2026 · Last updated Jun 18, 2026 · Updated 22 times
Summary
This early-phase study tested two drugs, abemaciclib and niraparib, given together before surgery in 8 people with hormone receptor-positive, HER2-negative breast cancer. The goal was to find the best dose and see if the combination could shrink tumors safely. The study focused on side effects and tumor response, offering a potential new approach to make surgery more effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE BREAST CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.